Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT

NCT01379391 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Allogeneic Hematopoietic Stem Cell Transplantation
Myeloablative
Delayed Platelet Engraftment

Interventions

DRUG: Recombinant Human Thrombopoietin (rHTPO)

Sponsor

Nanfang Hospital, Southern Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]